INCY

Incyte Corporation

61,51
-0,04 (-0,06%)

Incyte Corporation (INCY) Fundamentals

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
SHARE INFORMATION
Market CapUS$ 13.722.161.702
Shares Outstanding223.088.306
Float219.510.000
Percent Float98,4%
Short Interest0,00
Short Percent Float0,0%
Short Interest Ratio0,00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0,00
Latest Fiscal RevenueUS$ 808.673.000
Latest Fiscal EPSUS$ 0,10
Latest Fiscal Date2023-03-31
DIVIDENDS
Dividend (3 Years)US$ 0,00
Dividend (5 Years)US$ 0,00
Ex Dividend Date-
Dividend RateUS$ 0,00
Dividend Yield0,0%
Payment Cash-
HOLDERS
Institutions1.428
Institutional Holdings Date2023-03-31
Institutional Bought Previous 3 Months14.248.159
Institutional Holdings Percent154,5%
Institutional Sold Previous 3 Months36.516.100
Insider Holdings Date2023-03-31
Insider Bought Previous 3 Months416.480
Insider Holdings Percent15,1
Insider Sold Previous 3 Months168.441
Insider Shares Owned33.667.129
TRADING INFO
52 Week HighUS$ 86,29
52 Week LowUS$ 61,25
52 Week High ChangeUS$ -18,90
21 Day Moving AverageUS$ 64,7595
21 Day Extended Moving AverageUS$ 65,2748
50 Day Moving AverageUS$ 69,7402
50 Day Extended Moving AverageUS$ 68,9237
200 Day Moving AverageUS$ 74,5182
200 Day Extended Moving AverageUS$ 73,872
10 Day Average Volume1.805.518
20 Day Average Volume1.739.018
30 Day Average Volume1.928.793
50 Day Average Volume1.722.990
Alpha0.000145
Beta0.7159
Standard Deviation0.087610
R20.193065
7 Day Price ChangeUS$ -2,73
7 Day Percent Change-4,25%
21 Day Price ChangeUS$ -2,37
21 Day Percent Change-3,71%
30 Day Price ChangeUS$ -12,86
30 Day Percent Change-17,28%
Month to Date Price ChangeUS$ -12,86
Month to Date Percent Change-17,28%
Quarter to Date Price ChangeUS$ -10,72
Quarter to Date Percent Change-14,83%
180 Day Price ChangeUS$ -18,12
180 Day Percent Change-22,74%
200 Day Price ChangeUS$ -15,98
200 Day Percent Change-20,61%
Year to Date Price ChangeUS$ -18,77
Year to Date Percent Change-23,37%

Incyte Corporation (INCY) Key Ratios

PROFITABILITY
EBIT Margin14,8%
EBITDA Margin16,8%
Pre-Tax Profit Margin11,6%
Profit Margin Count0,03%
Gross Margin93,7%
Profit Margin TOT0,03%
INCOME STATEMENTS
RevenueUS$ 808.673.000
Revenue Per ShareUS$ 3,6249
Revenue (3 Years)US$ 0,00
Revenue (5 Years)US$ 0,00
FINANCIAL STRENGTH
Price to Tangible Book3,30
Total Debt To Equity0,00
Int Coverage237,70
Current Ratio4,00
Leverage Ratio1,30
Quick Ratio3,70
Long Term Debt To Capital0,01
VALUATION MEASURES
PE Ratio51,20
Enterprise ValueUS$ 10.727.609.492
Price to Sales4,78
Price to Free Cash0,00
PE High Last 5 Years0,00
Price To Book3,10
Price To Cash Flow-30,90
PE Low Last 5 Years0,00
Price to Tangible Book3,30
MANAGEMENT EFFECTIVENESS
Receivables Turnover5,90
Invoice Turnover2,90
Assets Turnover0,60
Return Assets6,00
Return on Equity7,80
Return on Capital7,75

Incyte Corporation (INCY) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
Auditor-
CEOHerve Hoppenot
Employees2094
Last Audit-
CIK0000879169
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Nanotechnology(541713)
CONTACT INFO
Address1801 Augustine Cut-Off
Wilmington, DE 19803
Websitehttps://www.incyte.com
Facsimile-
Telephone+1 302 498-6700
Emailmbooth@incyte.com
Kürzlich von Ihnen besucht
NASDAQ
INCY
Incyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Melden Sie sich bei ADVFN an
Jetzt registrieren
Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Support: +44 (0) 203 8794 460 | support@advfn.de

V: de D: 20230602 01:32:20